Inventor · disambiguated record
Michael Cooke
Also filed as: COOKE MICHAEL · COOKE MICHAEL CHARLES · COOKE MICHAEL P · COOKE MICHAEL PAUL
26 granted patents·51 pending applications·198 citations·filing 1988–2024
95Inventor score
Files withMAGENTA THERAPEUTICS INC34NOVARTIS AG11HEIDELBERG PHARMA RES GMBH4IRM LLC4VOR BIOPHARMA INC3
Top patents by PatentIndex Score
77 records- 0193US6148480AHinge construction with a snap-open, snap-shut feel, for a folding mobile phone handsetNEC CORP·Filed 1999·Granted Nov 21, 2000·85 cites·7 claims
- 0292US10899843B2Compositions and methods for the depletion of CD117+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Jan 26, 2021·8 cites·38 claims
- 0389US9580426B2Compounds that expand hematopoietic stem cellsBOITANO ANTHONY E·Filed 2013·Granted Feb 28, 2017·13 cites·20 claims
- 0488US12171839B2Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2022·Granted Dec 24, 2024·1 cites·11 claims
- 0588US8927281B2Method for expanding hematopoietic stem cellsBOITANO ANTHONY E·Filed 2009·Granted Jan 6, 2015·11 cites·22 claims
- 0686US10058573B1Dosing regimens for the mobilization of hematopoietic stem cellsMAGENTA THERAPEUTICS INC·Filed 2017·Granted Aug 28, 2018·7 cites·9 claims
- 0785US12251448B2Compositions and methods for the depletion of CD5+ cellsHEIDELBERG PHARMA RES GMBH·Filed 2021·Granted Mar 18, 2025·1 cites·13 claims
- 0884US11958908B2Compositions and methods for the depletion of CD117+ cellsCRISPR THERAPEUTICS AG·Filed 2020·Granted Apr 16, 2024·1 cites·26 claims
- 0982US11752162B2Compounds and compositions for treating solid tumors by intratumoral administrationNOVARTIS AG·Filed 2018·Granted Sep 12, 2023·1 cites·21 claims
- 1080US12403200B2Methods and compositions for treating autoimmune diseasesVOR BIOPHARMA INC·Filed 2021·Granted Sep 2, 2025·1 cites·24 claims
- 1179US10434185B2Compositions and methods for the depletion of CD137+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Oct 8, 2019·1 cites·29 claims
- 1279US2025064964A1Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1379US2025295698A1Dosing regimens for the mobilization of hematopoietic stem cellsENSOMA INC·Filed 2024·Application pending·0 cites
- 1478US2024360238A1Compositions and methods for the depletion of cd117+ cellsCRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1577US11260079B2Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2019·Granted Mar 1, 2022·1 cites·23 claims
- 1677US9834755B2Compositions and methods for enhanced generation of hematopoietic stem/progenitor cellsHUTCHINSON FRED CANCER RES·Filed 2012·Granted Dec 5, 2017·2 cites·22 claims
- 1777US2025082767A1Compositions and methods for the depletion of cd5+ cellsHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 1876US12209135B2Anti-CD45 antibodies and conjugates thereofVOR BIOPHARMA INC·Filed 2024·Granted Jan 28, 2025·0 cites·22 claims
- 1976US6451558B1Genes in the control of hematopoiesisNOVARTIS AG·Filed 1999·Granted Sep 17, 2002·34 cites·15 claims
- 2075US10576161B2Compositions and methods for the depletion of CD137+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Mar 3, 2020·1 cites·24 claims
- 2174US2024009215A1Compounds and compositions for treating solid tumors by intratumoral administrationNOVARTIS AG·Filed 2023·Application pending·0 cites
- 2273US2025032549A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsENSOMA INC·Filed 2024·Application pending·0 cites
- 2372US2023130646A1Dosing regimens for the mobilization of hematopoietic stem cellsMAGENTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2470US2021187033A1Compounds that expand hematopoietic stem cellsNOVARTIS AG·Filed 2020·Application pending·0 cites
- 2566US2024002843A1Compositions and methods for the treatment of hemoglobinopathiesNOVARTIS AG·Filed 2022·Application pending·0 cites
- 2666US2024075157A1Fc silenced antibody drug conjugates (adcs) and uses thereofMAGENTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2763US2022096559A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2860US2020276326A1Compositions and methods for the depletion of cd5+ cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2960US2019336536A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3059US2020289664A1Compositions and methods for the depletion of cd137+ cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3157US11357864B2Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2017·Granted Jun 14, 2022·0 cites·23 claims
- 3256US2023330185A1Methods and compositions for transducing hematopoietic stem and progenitor cells in vivoMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3356US2004128175A1Method for monitoring workplace safetyFiled 2002·Application pending·0 cites
- 3456US2019167726A1Dosing Regimens for the Mobilization of Hematopoietic Stem CellsMAGENTA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3556US2021283267A1Therapeutic methods using antibody drug conjugates (adcs)MAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3656US2022177578A1Anti-cd117 antibodies and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3756US2022177575A1Anti-cd117 antibodies and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3856US2017239296A1Compounds that expand hematopoietic stem cellsNOVARTIS AG·Filed 2017·Application pending·0 cites
- 3956US2022175946A1Conditioning methods for gene therapyMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4055US12006370B2Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapyHEIDELBERG PHARMA RES GMBH·Filed 2021·Granted Jun 11, 2024·0 cites·30 claims
- 4154US12403185B2Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapyHEIDELBERG PHARMA RES GMBH·Filed 2021·Granted Sep 2, 2025·0 cites·23 claims
- 4254US2020376135A1Fc silenced antibody drug conjugates (adcs) and uses thereofMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4353US12291576B2Anti-CD45 antibodies and conjugates thereofVOR BIOPHARMA INC·Filed 2021·Granted May 6, 2025·0 cites·26 claims
- 4453US4924190AAmplifiersPLESSEY OVERSEAS·Filed 1988·Granted May 8, 1990·10 cites·3 claims
- 4553US2022249683A1T-cell depleting therapiesMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4653US2022175944A1Anti-cd117 antibody-drug conjugates and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4753US2021260212A1Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapyMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4852US2022226493A1Anthracycline antibody-drug conjugates and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4952US2023390412A1Compositions and methods for allogeneic transplantationMAGENTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 5052US2021095039A1Anti-cd252 antibodies, conjugates, and methods of useMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 77 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Michael Cooke files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →